Hologic Showcases Growing Portfolio of Women’s Health Products at 2019 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting

Company to host timely educational panel on breast density featuring
leading clinicians

MARLBOROUGH, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ACOG2019?src=hash” target=”_blank”gt;#ACOG2019lt;/agt;–Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company
primarily focused on improving women’s health and well-being, will
showcase its comprehensive portfolio of healthcare solutions at the 67th
Annual American College of Obstetricians and Gynecologists (ACOG)
Clinical and Scientific Meeting. The meeting takes place in Nashville,
Tennessee, from May 3 to 6.

“Each year, we look forward to engaging with OB-GYNs who are critical
partners of ours in improving the health and well-being of women around
the globe,” said Steve MacMillan, Chairman, President and CEO of
Hologic. “Beyond showcasing our latest products and innovations, we’re
looking forward to leading a timely discussion on the significant role
breast density can play in cancer detection, so OB-GYNs can feel
confident discussing this important topic with their patients.”

The panel, “Are You Prepared? A Date with Breast Density,” will take
place on May 4 from 5:15 to 6:00 p.m. in room 103 of the Music City
Center. It will feature an engaging discussion of the risks associated
with breast density, appropriate screening pathways, and updates to
legislation. Meg Eckenroad, Hologic’s Vice President of Women’s Health &
Professional Relations, will moderate the panel, which will include Dr.
Regina Hooley, Associate Professor of Radiology and Biomedical Imaging
and Vice Chair for Clinical Affairs at Yale New Haven Hospital; and Dr.
DaCarla Albright, Associate Professor of Clinical Obstetrics and
Gynecology at Penn Medicine. The panel comes on the heels of the FDA’s
proposed rule to update the Mammography Quality Standards Act, which
highlights the risks of breast density and emphasizes important advances
in mammography technology.

Hologic’s booth will showcase the Company’s comprehensive portfolio of
women’s health products from its four divisions, including:

  • Breast & Skeletal Health Solutions: Hologic’s Genius™ 3D
    Mammography™ exam is the only mammogram that detects more invasive
    cancers, reduces false positives, and is FDA approved as superior to
    conventional 2D mammography for all women, including those with dense
    breasts.1,2,3 Hologic also will exhibit its SmartCurve™
    breast stabilization system, which is offered exclusively with the
    Genius exam and is clinically proven to deliver a more comfortable
    mammogram without compromising image quality, workflow, or dose.4 Hologic’s
    skeletal health portfolio will also be displayed, including
    the BodyLogic™ scan, which is available on the Horizon® DXA system.
  • Gynecological Surgical Solutions: New innovations on display
    will include the Omni™ hysteroscope, a three-in-one modular scope with
    advanced visualization capabilities designed for both diagnostic and
    therapeutic hysteroscopic procedures; the Fluent® fluid management
    system, designed to provide operating room (OR) staff with simplified
    and effective fluid management to support hysteroscopic procedures;
    and Nitronox™, a nitrous oxide and oxygen analgesia system to support
    a variety of in-office medical and aesthetic procedures where pain
    management and anxiety are a concern.
  • Diagnostic Solutions: Hologic’s Aptima® Mycoplasma genitalium
    assay was granted FDA clearance in January, becoming the first and
    only FDA-cleared test to detect Mycoplasma genitalium, an
    under-recognized but increasingly common sexually transmitted
    infection (STI). This newest Aptima assay joins a growing suite of
    market-leading tests offered by Hologic to help combat the rise of
    STIs in the U.S. The division is also continuing its We Can Change
    This STAT
    initiative, which
    aims to reduce the number of cervical cancer deaths by empowering
    women to commit to regular annual exams and ask their doctors about
    testing with Pap+HPV Together.5 Additional information is
    available at ChangeThisSTAT.com.
  • Medical Aesthetics Solutions: Cynosure, Hologic’s medical
    aesthetics division, will demonstrate its latest innovation, TempSure®
    Surgical RF technology. Launched in December, TempSure Surgical
    technology lessens the sparking and charring normally experienced
    during procedures, resulting in quicker recovery. The system is
    designed to improve patient satisfaction and aesthetic outcomes,
    and can be used by clinicians across a variety of specialties
    including plastic surgery, dermatology, gynecology, and ophthalmology.
    The booth will also feature SculpSure®, a clinically proven,
    non-surgical body contouring (lipolysis) treatment designed to
    permanently eliminate fat cells in problem areas; and the Icon™
    aesthetic system, which offers fast, state-of-the art treatments for
    vessel and pigment clearance, surgical and acne scarring, stretch
    marks, wrinkle reduction, and permanent hair reduction.

Products will be on display in Booth 1510 at the Music City Center.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily
focused on improving women’s health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.

Forward-Looking Statements

This news release may contain forward-looking information that involves
risks and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated in
any particular manner with respect to an individual patient, as the
actual effect of the use of the products can only be determined on a
case-by-case basis. In addition, there can be no assurance that these
products will be commercially successful or achieve any expected level
of sales. Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or statements
are based.

Hologic, 3D, 3D Mammography, Aptima, BodyLogic, Fluent, Genius, Horizon,
Icon, MyoSure, NovaSure, Omni, SmartCurve, SculpSure, TempSure, and The
Science of Sure are trademarks and/or registered trademarks of Hologic,
Inc. in the United States and/or other countries. Nitronox is a
trademark of Porter Instrument, Parker Hannifin Corporation.

SOURCE: Hologic, Inc.

References:

The Genius™ 3D Mammography™ exam (a.k.a. Genius™ exam) is acquired on
the Hologic® 3D Mammography™ system and consists of a 2D and 3D™ image
set, where the 2D image can be either an acquired 2D image or a 2D image
generated from the 3D™ image set. The Genius™ exam is only available on
the Hologic® 3D Mammography™ system. Please consult your physician for a
complete list of benefits and risks associated with mammography.

  1. Results from Friedewald, SM, et al. “Breast cancer screening using
    tomosynthesis in combination with digital mammography.” JAMA 311.24
    (2014): 2499-2507; a multi-site (13), non-randomized, historical
    control study of 454,000 screening mammograms investigating the
    initial impact the introduction of the Hologic Selenia® Dimensions ®
    on screening outcomes. Individual results may vary. The study found an
    average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6)
    additional invasive breast cancers per 1000 screening exams were found
    in women receiving combined 2D FFDM and 3D™ mammograms acquired with
    the Hologic 3D Mammography™ system versus women receiving 2D FFDM
    mammograms only.
  2. Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening
    with tomosynthesis (3D mammography) with acquired or synthetic 2D
    mammography compared with 2D mammography alone (STORM-2): a
    population-based prospective study. Lancet Oncol. 2016
    Aug;17(8):1105-13.
  3. U.S. Food & Drug Administration Premarket Approval (PMA). FDA.gov https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003S005
    accessed June 5, 2017.
  4. Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00119
    Rev 001 (2017).
  5. The American College of Obstetricians and Gynecologists. Practice
    bulletin No. 157: Cervical cancer screening and prevention. Obstetrics
    and Gynecology. 2016;127(1):185-7.

Contacts

Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978
(mobile)
[email protected]

Investor Contact:
Michael Watts
858.410.8588
[email protected]

error: Content is protected !!